NEW PEPTIDE-BASED CANCER VACCINE: PHASE I AND EARLY PHASE II CLINICAL TRIALS FOR CASTRATION-RESISTANT PROSTATE CANCER

被引：0
|
作者：
Noguchi, M. [1 ,2 ]
Suekane, S. [2 ]
Moriya, F. [2 ]
Sasada, T. [3 ]
Yamada, A. [3 ]
Itoh, K. [3 ]
机构：
[1] Kurume Univ, Sch Med, Res Ctr Innovat Canc Therapy, Div Clin Res, Kurume, Fukuoka 830, Japan
[2] Kurume Univ, Sch Med, Dept Urol, Kurume, Fukuoka 830, Japan
[3] Kurume Univ, Sch Med, Dept Immunol & Immunotherapy, Kurume, Fukuoka 830, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：74 / 74
页数：1
相关论文
共 50 条
  • [1] The Prostate Cancer Clinical Trials Working Group (PCCTWG) consensus criteria for phase II clinical trials for castration-resistant prostate cancer
    Scher, H. I.
    Halabi, S.
    Tannock, I.
    Morris, M.
    Higano, C.
    Kelly, W.
    Sternberg, C.
    Eisenberger, M.
    Martin, A.
    Hussain, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] PHASE I CLINICAL TRIAL OF NOVEL CDCA1 DERIVED EPITOPE PEPTIDE VACCINE THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER
    Obara, Wataru
    Sato, Fuminori
    Yoshida, Koji
    Tsunoda, Takuya
    Iwasaki, Kazuhiro
    Takata, Ryo
    Mimata, Hiromitsu
    Nakamura, Yusuke
    Fujioka, Tomoaki
    JOURNAL OF UROLOGY, 2011, 185 (04): : E510 - E510
  • [3] Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer
    Dahut, William L.
    Madan, Ravi A.
    Karakunnel, Joyson J.
    Adelberg, David
    Gulley, James L.
    Turkbey, Ismail B.
    Chau, Cindy H.
    Spencer, Shawn D.
    Mulquin, Marcia
    Wright, John
    Parnes, Howard L.
    Steinberg, Seth M.
    Choyke, Peter L.
    Figg, William D.
    BJU INTERNATIONAL, 2013, 111 (08) : 1269 - 1280
  • [4] Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial
    Noguchi, Masanori
    Arai, Gaku
    Egawa, Shin
    Ohyama, Chikara
    Naito, Seiji
    Matsumoto, Kazumasa
    Uemura, Hirotsugu
    Nakagawa, Masayuki
    Nasu, Yasutomo
    Eto, Masatoshi
    Suekane, Shigetaka
    Sasada, Tetsuro
    Shichijo, Shigeki
    Yamada, Akira
    Kakuma, Tatsuyuki
    Itoh, Kyogo
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (05) : 847 - 857
  • [5] Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial
    Masanori Noguchi
    Gaku Arai
    Shin Egawa
    Chikara Ohyama
    Seiji Naito
    Kazumasa Matsumoto
    Hirotsugu Uemura
    Masayuki Nakagawa
    Yasutomo Nasu
    Masatoshi Eto
    Shigetaka Suekane
    Tetsuro Sasada
    Shigeki Shichijo
    Akira Yamada
    Tatsuyuki Kakuma
    Kyogo Itoh
    Cancer Immunology, Immunotherapy, 2020, 69 : 847 - 857
  • [6] A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
    Hideyuki Akaza
    Hirotsugu Uemura
    Taiji Tsukamoto
    Seiichiro Ozono
    Osamu Ogawa
    Hideki Sakai
    Mototsugu Oya
    Mikio Namiki
    Satoshi Fukasawa
    Akito Yamaguchi
    Hiroji Uemura
    Yasuo Ohashi
    Hideki Maeda
    Atsushi Saito
    Kentaro Takeda
    Seiji Naito
    International Journal of Clinical Oncology, 2016, 21 : 773 - 782
  • [7] A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
    Akaza, Hideyuki
    Uemura, Hirotsugu
    Tsukamoto, Taiji
    Ozono, Seiichiro
    Ogawa, Osamu
    Sakai, Hideki
    Oya, Mototsugu
    Namiki, Mikio
    Fukasawa, Satoshi
    Yamaguchi, Akito
    Uemura, Hiroji
    Ohashi, Yasuo
    Maeda, Hideki
    Saito, Atsushi
    Takeda, Kentaro
    Naito, Seiji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (04) : 773 - 782
  • [8] Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase I/II clinical trial
    Zhang, Hongyong
    Wang, Yu
    Ghosh, Paramita
    Lara, Primo N., Jr.
    Pasquinelli, Patricia
    Beckett, Laurel
    White, Ralph W. deVere
    Pan, Chong-Xian
    CANCER RESEARCH, 2010, 70
  • [9] Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase I/II clinical trial
    Pan, C.
    Ghosh, P.
    Suga, J. M.
    Paequinelli, P.
    Beckett, L.
    White, R. Deere
    Lara, P., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer.
    Scher, Howard I.
    Mccormack, Robert Thomas
    Molina, Arturo
    Smith, Matthew Raymond
    Dreicer, Robert
    Saad, Fred
    De Wit, Ronald
    Fizazi, Karim
    Aftab, Dana T.
    Limon, Ana
    Fleisher, Martin
    De Bono, Johann S.
    Kelloff, Gary J.
    Heller, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345